Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation + bezlotoxumab
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Rectal, Oral, Nasogastric
01
Overview
This is a combination therapy consisting of fecal microbiota transplantation (FMT) and bezlotoxumab. FMT is a procedure in which processed stool from a healthy donor is introduced into the gastrointestinal tract of a patient, primarily to restore healthy gut flora and treat recurrent or refractory Clostridioides difficile infection (CDI). The mechanism involves repopulating the colon with beneficial bacteria to outcompete C. difficile and restore microbial balance[1][2][3]. Bezlotoxumab is a human monoclonal antibody that binds to and neutralizes C. difficile toxin B, thereby reducing recurrence of CDI by preventing toxin-mediated damage. This combination aims to both directly neutralize C. difficile toxins (bezlotoxumab) and restore gut microbial diversity (FMT), potentially providing synergistic benefit for patients at high risk for recurrent CDI.
- Other names
- FMT + bezlotoxumabfecal transplant + bezlotoxumab
02
Targets
TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on fecal microbiota transplantation + bezlotoxumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation + bezlotoxumab.